Syndax Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Hey, everyone. Thank you for joining us here at the Goldman Sachs Global Healthcare Conference. I'm really, really excited to be joined by the whole team from Syndax Pharmaceuticals to give us an update on kind of an interesting first half of the year heading into hopefully even more interesting second half of the year.
Questions & Answers
So let's get started with the kind of big picture view. So team, if you could you then walk through kind of the current Syndax clinical pipeline focusing both on ongoing and kind of planned clinical trials given where you are today?
Yes, Madhu. First, thanks so much for inviting us to participate. It's great to see you in your new assignment. We currently have 2 programs in clinical development, 5613 and axatilimab. 5613 is our Menin MLL
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
